OVID Health Systems

What OVID Health Systems does

OVID Health Systems operates OVID Clinics Berlin, a private psychiatric practice and intensive day clinic located at Boxhagener Strasse 82 in Berlin Friedrichshain. The clinic delivers contemporary psychiatry, psychotherapy, and psychosomatic medicine, with a core specialisation in ketamine- and psilocybin-augmented psychotherapy. Its treatment portfolio spans outpatient consultations, an intensive 4-12 week day clinic programme with capacity for up to 16 patients, and Germany's first BfArM-approved psilocybin compassionate use programme for treatment-resistant depression under Prof. Dr. med. Gerhard Gründer. Treatment modules include guideline-based psychotherapy (behavioural, systemic, depth-psychological), mindfulness and relaxation, body and movement therapy, creative therapies (art, music, bibliotherapy), breathwork, virtual reality, and medication tapering, delivered by a multidisciplinary team operating in German, English, Spanish, and Turkish.

The business is structured across three interconnected German legal entities — OVID Clinic Berlin GmbH (private practice), OVID Tagesklinik GmbH & Co. KG (day clinic operations), and OVID Beteiligungsgesellschaft mbH (intermediate holding) — under shared management by Prof. Dr. Gerhard Gründer, Dr. Andrea Jungaberle, and Markus Kopf. Revenue is generated exclusively from privately insured (PKV), Beihilfe, and self-paying patients, as statutory health insurance (GKV) does not cover these services. Pricing is per treatment course: outpatient ketamine-augmented psychotherapy at €6,500-€7,500, day clinic programmes at €12,000-€15,000 for 4-6 weeks, and the psilocybin compassionate use programme at approximately €24,000 for 8 weeks. Distribution is direct-to-patient through the Berlin facility, supported by physician referral partnerships (a dedicated For Referrers portal and CME-accredited OVID Academy), and strategic research collaborations with Charité Berlin and the MIND Foundation stemming from the EPIsoDe study (2021-2024). The company is privately held with no disclosed external investors.

Name

OVID Health Systems

Legal name

OVID Clinic Berlin GmbH

Website

https://ovid-clinics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

OVID Clinics Berlin is a private psychiatric practice and day clinic in Berlin Friedrichshain that delivers ketamine- and psilocybin-augmented psychotherapy, outpatient psychiatry, and intensive multi-modal day clinic programmes exclusively to privately insured and self-paying patients. The clinic operates Germany's first BfArM-approved psilocybin compassionate use programme under Prof. Dr. Gerhard Gründer.

Ownership category

akta.pro rank

Product category

Psychiatric & Psychotherapeutic Day Clinic Services

NAICS

Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Mental Health Practitioners (except Physicians) (621330)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industries

Outpatient Mental Health & Counseling Clinics (HLAFABAC), Behavioral Health Partial Hospitalization & Intensive Outpatient Programs (PHP/IOP) (HLAFACAJ)

Keywords

• Psychedelic-assisted psychotherapy
• Ketamine-augmented psychotherapy
• Psilocybin therapy
• Psychiatric day clinic
• Treatment-resistant depression

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Private Insurance Billing (PKV): Direct billing to private health insurers for psychiatric and psychotherapeutic treatments. Services are exclusively available to privately insured patients, with the clinic handling all insurance communications and GOÄ fee schedule billing.
2. Self-Pay / Out-of-Pocket: Self-funding patients pay directly for treatments including ketamine-augmented psychotherapy (€6,500-7,500), day clinic programmes (€12,000-15,000 for 4-6 weeks), and psilocybin compassionate use (approximately €24,000 for 8 weeks).
3. Civil Service Insurance (Beihilfe): Billing to civil service insurance schemes in addition to or as supplement to private insurance coverage for eligible patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

OVID Clinics Berlin operates a private psychiatric practice and day clinic in Berlin Friedrichshain providing outpatient psychiatric and psychotherapeutic consultations alongside intensive 4–12 week day clinic programmes. The clinic sells ketamine-augmented psychotherapy (KAP) and Germany's first BfArM-approved psilocybin compassionate use programme for treatment-resistant depression, integrating individual therapy, group therapy, mindfulness, body therapy, creative therapies, breathwork, and virtual reality. Services are exclusively available to privately insured (PKV) patients and self-funding individuals, with no statutory health insurance coverage.

Product overview

OVID Clinic Berlin operates as an integrated private practice and day clinic for contemporary psychiatry, psychotherapy and psychosomatic medicine. The core offering consists of two main service lines: the outpatient Private Practice providing regular psychiatric and psychotherapeutic consultations, and the Day Clinic offering intensive multi-week treatment programmes (typically 4-12 weeks). Within the day clinic framework, patients receive up to three individual therapy sessions per week supplemented by group therapy, mindfulness practices, creative therapies, and body movement therapies. The clinic specializes in psychedelic-augmented psychotherapy, offering Germany's first officially approved compassionate use programme for psilocybin alongside ketamine-augmented psychotherapy (KAP). Treatment is available in German, English, Spanish and Turkish, exclusively serving privately insured patients and self-funding individuals.

Differentiator

Problem solved

Functional benefit

Brands

• Ketamine-Augmented Psychotherapy (KAP): Ketamine-augmented psychotherapeutic sessions offered in individual and group settings for treatment-resistant conditions.
• Psilocybin Compassionate Use Programme

Products and services

• OVID Private Practice — Outpatient Psychiatry & Psychotherapy Private outpatient practice for contemporary psychiatry, psychotherapy and psychosomatic medicine offering psychiatric consultations, guideline-based psychotherapy, and medication management for privately insured patients and self-funding individuals. Services delivered in German, English, Spanish and Turkish.
• OVID Day Clinic — Intensive Psychiatric Programme Intensive day hospital treatment programme lasting 4–12 weeks, providing up to three individual psychotherapy sessions per week combined with group therapy, mindfulness, body & movement therapy, creative therapies, specialist psychiatric care, and optional psychedelic-augmented psychotherapy. Capacity for up to 16 patients simultaneously.
• Ketamine-Augmented Psychotherapy (KAP) Clinically rigorous ketamine-augmented psychotherapy combining ketamine administration with intensive psychotherapeutic support to dissolve entrenched thought patterns and promote neural plasticity. Offered in individual and group settings at €6,500–7,500 per course.
• Psilocybin Compassionate Use Programme Germany's first officially approved compassionate use programme with psilocybin for treatment-resistant depression, led by Prof. Dr. med. Gerhard Gründer under BfArM approval. Delivered as a multi-week day clinic treatment at approximately €24,000 for an 8-week programme.
• Medication Tapering Service Needs-oriented, medically supervised discontinuation of psychiatric medication (antidepressants, neuroleptics) integrated within the clinic's treatment approach.

Quantifiable outcome

• EPIsoDe study: Largest psilocybin therapy study for treatment-resistant depression in Germany, conducted at Central Institute of Mental Health Mannheim in collaboration with Charité Berlin and MIND Foundation (2021–2024)

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• MIND FoundationcoreStrategic or Co-development PartnerNonprofit partner organization dedicated to research and education in mental health. MIND promotes the legal, safe, and evidence-based use of psychedelics in therapy and human development. The partnership supports OVID's clinical work and research activities, including the EPIsoDe study collaboration. MIND is listed as a partner on the clinic's website and referenced in media coverage.
• Charité BerlincoreStrategic or Co-development PartnerPartnership with Prof. Dr. Wattjes and his team at Charité for imaging techniques and diagnostics. Clinical collaboration supporting comprehensive patient assessment and treatment planning. Charité is one of Europe's largest university hospitals.
• It's ComplicatedminorStrategic or Co-development PartnerMental-health platform that connects clients with vetted therapists for online and in-person sessions. Partnership improves access to psychotherapeutic care for broader patient population.
• DATPPP e.V.minorOthersGerman Association of Part-Time Psychiatric, Psychotherapy, and Psychosomatic Facilities. Professional association committed to the further development and quality assurance of part-time inpatient care. Supports professional standards and networking.
• Blaupause Therapy & CoachingminorChannel Partner/ Reseller/ DistributorHolistic private practice in Berlin offering integrated coaching and body-psychotherapy for mental clarity, resilience, and personal development. Inter-referral relationship for complementary care.
• Dr. Maria Schefter & Psychotherapeut:InnenminorChannel Partner/ Reseller/ DistributorPrivate practice for psychotherapy, trauma therapy, EMDR, and coaching located in Berlin-Mitte and Berlin-Prenzlauer Berg. Inter-referral relationship for complementary therapeutic services.
• Dr. Viola Kappel & ColleaguesminorChannel Partner/ Reseller/ DistributorPrivate practice in Berlin-Schöneberg led by Dr. phil. Dipl.-Psych. Viola Kappel offering specialized behavioral therapy, trauma therapy, couples therapy, diagnostics, and coaching on-site and online.
• Freiraum Psychotherapie BerlinminorChannel Partner/ Reseller/ DistributorCognitive behavioral therapy practice supporting people in Berlin-Friedrichshain with evidence-based, empathic psychotherapy. Geographic proximity and complementary therapeutic approach support inter-referral.
• nu.well Psychotherapy & CoachingminorChannel Partner/ Reseller/ DistributorModern practice in Berlin-Charlottenburg offering psychotherapeutic support and individual coaching for individuals, couples, and groups. Inter-referral relationship for complementary services.
• Psychotherapy KöhneminorChannel Partner/ Reseller/ DistributorBerlin-based private practice led by Dr. Svenja Köhne offering evidence-based behavioral therapy and individual psychological counseling for adults.
• Therapie FriedrichshainminorChannel Partner/ Reseller/ DistributorPrivate practice in Berlin offering individual psychotherapeutic treatments for adults. Geographic proximity to OVID's Friedrichshain location supports inter-referral for complementary care.
• Friesenplatz Day ClinicminorChannel Partner/ Reseller/ DistributorPrivate, part-time facility in Cologne offering specialized programs for mental illnesses such as depression, anxiety, and trauma-related disorders. Inter-clinic referral relationship for patients requiring care in different geographic locations.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Asklepios Kliniken: One of Germany's largest private hospital operators with significant psychiatric and psychosomatic service lines across multiple sites. Comparable as a large multi-site German psychiatric provider, though lacking OVID's psychedelic specialization.
• Median Kliniken: Major German private rehabilitation and psychosomatic clinic chain. Comparable as a German private-pay psychiatric/psychosomatic day-clinic operator, though primarily conventional rather than psychedelic-augmented therapy.
• atai Life Sciences: Clinical-stage biopharmaceutical platform developing psychedelic and non-psychedelic mental health therapies. Operates a portfolio of psychedelic programmes (including VLS-01, DM-001) and shares OVID's psychedelic-augmented therapy thesis but at much larger scale and broader indication set.
• Schoen Clinic: Germany's largest family-run hospital group with extensive psychiatric and psychosomatic inpatient and day-clinic services. Comparable as a German psychiatric care provider with day-clinic infrastructure, though focused on conventional rather than psychedelic-augmented therapy.

Direct peers

• Compass Pathways: Publicly listed developer of psilocybin therapy (COMP360) for treatment-resistant depression. Directly comparable as a European-headquartered, clinical-stage psychedelic-assisted therapy company targeting the same TRD patient population with regulatory-first positioning.
• GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT) and other psychedelic therapies for TRD. Directly comparable as a psychedelic-focused TRD company with regulatory/clinical-trial positioning parallel to OVID's psilocybin programme.

Emerging players

• Clerkenwell Health: UK-based psychedelic clinical trials company running therapy trials for depression and other indications. Comparable as a European psychedelic-therapy clinical operator, though focused on trial delivery rather than commercial patient treatment.
• Awakn Life Sciences: UK/Canada-based clinical-stage company developing psychedelic-assisted therapies for addiction and mental health disorders. Comparable as an emerging European psychedelic-therapy operator with overlapping clinical indications (depression, addiction).
• Synthesis Institute: Netherlands-based psychedelic therapy training and retreat organization offering psilocybin truffle programmes in a legal Dutch framework. Comparable as a European commercial psychedelic-therapy provider, though operating under Dutch psilocybin-truffle regulation rather than German medical pathways.
• MIND Foundation: Berlin-based nonprofit research and education organization for psychedelic-assisted therapy, OVID's stated partner. Comparable as a European psychedelic-therapy ecosystem player; MIND focuses on training, research, and education while OVID delivers clinical treatment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ovid_health
• Facebookfacebook.com/ovidhealtheu
• LinkedInlinkedin.com/company/66876654

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OVID Health Systems